Denise Haefliger-Nardelli

Lausanne, VD 1011, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Correction: Sathiyanadan et al. Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. Int. J. Mol. Sci. 2022, 23, 2930.

Correction: Sathiyanadan et al. Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. Int. J. Mol. Sci. 2022, 23, 2930.

Journal: International journal of molecular sciences

Published: February 26, 2026

Characterization of Ty21a immunostimulatory effects in the mouse bladder.

Characterization of Ty21a immunostimulatory effects in the mouse bladder.

Journal: Frontiers in immunology

Published: May 15, 2025

Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

Journal: Frontiers in immunology

Published: May 13, 2025

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2023

Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.

Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.

Journal: Frontiers in immunology

Published: November 08, 2023

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.

Journal: International journal of molecular sciences

Published: November 28, 2022

Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.

Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.

Journal: European urology open science

Published: September 12, 2022

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.

Journal: Journal for immunotherapy of cancer

Published: August 02, 2022

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.

Journal: Journal for immunotherapy of cancer

Published: June 09, 2022

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth.

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth.

Journal: International journal of molecular sciences

Published: February 02, 2022

Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.

Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.

Journal: European urology open science

Published: October 15, 2021

Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.

Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.

Journal: Oncoimmunology

Published: April 28, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026